Close

Nektar Therapeutics (NKTR) Tops Q3 EPS by 4c

Go back to Nektar Therapeutics (NKTR) Tops Q3 EPS by 4c

Nektar Therapeutics Reports Financial Results for the Third Quarter of 2016

November 3, 2016 4:10 PM EDT

SAN FRANCISCO, Nov. 3, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2016.

Cash and investments in marketable securities at September 30, 2016 were $253.5 million as compared to $308.9 million at December 31, 2015. Our cash and investments in marketable securities at September 30, 2016 do not include net proceeds of approximately $189.1 million from the recent sale and issuance of our common stock on October 24, 2016.

"Our pipeline is rapidly advancing with several important data catalysts and potential approvals expected over the next several quarters," said Howard W. Robin,... More